Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Overdependence on China for drug ingredients worries NSA -Sushmi Dey

Overdependence on China for drug ingredients worries NSA -Sushmi Dey

Share this article Share this article
published Published on Nov 26, 2014   modified Modified on Nov 26, 2014
-The Times of India

NEW DELHI: India runs the risk of a severe shortage of medicines because of its over dependence on China for sourcing raw material for drugs, national security adviser (NSA) Ajit Doval has warned, TOI has learnt.

According to the NSA, India should take immediate concrete steps to create adequate infrastructure to become self-sufficient for manufacturing medicines which are essential in nature.

"The national security adviser had highlighted concerns related to overdependence on China for supply of active pharmaceutical ingredient (API). Following this, a core committee of experts was formed under the health ministry and a policy would soon be finalized to boost domestic manufacturing of bulk drugs used in medicine formulations," a senior official in the government privy to the developments, told TOI.

Currently, India imports over 80-85% of API, or raw material used in medicines, from China. This is crucial because any kind of tension or adverse circumstances between the two countries have potential to lead to a crisis in public health in India. Experts say China has antagonized many of its neighbours in the past and India should take a call based on its economic and strategic relationship with the country.

In 2010, the Chinese government had blocked exports to Japan of a crucial category of minerals used in products like hybrid cars, wind turbines and guided missiles, following tensions between the two countries.

Sources said the PMO as well as health ministry had taken cognizance of the issue. To start with, the government is set to roll out a separate policy to revive the domestic API manufacturing industry. "The committee and task force set up by the government for preparing the policy have finalized their recommendations and gone to the PMO," the official said.

The proposed policy will address the concerns of bulk drug manufacturing by way of incentives and creating infrastructure through bulk drug parks, etc. The proposal will also evaluate other issues related to anti-dumping duties and environmental clearances.

India was once a favoured destination for sourcing low-cost, good quality raw material for manufacturing medicines. However, China has taken over this bulk drug market globally in the past few years by creating huge capacities. Now, while some pharmaceutical companies manufacture selective API for captive usage, most of it is imported from China. The reason is that landed price of API from China in India is 15-20% less than its production cost here, making it more viable for companies to import.

The domestic API manufacturing industry, mostly based out of Hyderabad and Ahmedabad, currently accounts for 8-10% of India's Rs 79,000-crore pharmaceutical market. The rest comprises formulations. In 2007, when the total domestic pharma market was around Rs 35,000 crore, APIs accounted for over 15-20%.

However, some believe price benefit is just one reason. Concerns such as environmental obstacles and lack of infrastructure dissuade domestic manufacturers. The idea is to facilitate the industry by ensuring adequate power and water supply, providing logistics and helping companies in capacity building to bring down cost of production.


The Times of India, 26 November, 2014, http://timesofindia.indiatimes.com/india/Overdependence-on-China-for-drug-ingredients-worries-NSA/articleshow/45278715.cms


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close